GlassScriptPhysician profile
Edward Liebers
NPI 1174528764
$5,658.70
in general payments reported to CMS, 2019-2025
58 companies · $713 in 2025
The $713 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $639 · 2021: $665 · 2022: $622 · 2023: $894 · 2024: $1,006 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.80 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $297.00 | 2019-2025 | Polivy, Alecensa, Tecentriq |
| Astrazeneca Pharmaceuticals LP | $284.86 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $281.66 | 2019-2024 | Ninlaro |
| Pfizer INC. | $279.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $263.90 | 2019-2025 | Opdivo |
| Astellas Pharma US INC | $210.35 | 2019-2025 | Xospata, Padcev, Vyloy |
| Janssen Biotech, INC. | $198.06 | 2019-2025 | Darzalex, Talvey, Imbruvica |
| Abbvie INC. | $193.09 | 2019-2025 | |
| Incyte Corporation | $185.50 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Daiichi Sankyo INC. | $168.83 | 2022-2025 | Enhertu |
| Glaxosmithkline, LLC. | $164.64 | 2020-2025 | Jemperli, Ojjaara |
| Emd Serono, INC. | $160.62 | 2020-2025 | Bavencio |
| Array Biopharma INC | $159.84 | 2021-2024 | Mektovi, Braftovi, Lorbrena |
| Novartis Pharmaceuticals Corporation | $157.92 | 2019-2025 | |
| Genzyme Corporation | $155.08 | 2019-2024 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Liebers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.